So far, one CSF1R inhibitor (pexidartinib) has obtained FDA approval but only in the setting of tenosynovial giant cell tumors, a tumor type that aberrantly expresses CSF1 in neoplastic cells due to chromosomal translocations involving the CSF1 gene [31, 32]. Here, CSF1 is linked to neoplasm.